Cynata starts Phase I of mesenchymal stem cells to treat GvHD

Cynata Therapeutics Ltd. (ASX:CYP) began a Phase I trial to evaluate CYP-001 in about 16 patients with steroid-resistant grade II-IV acute graft-versus-host disease (GvHD) after receiving allogeneic hematopoietic stem cell transplant for a hematological disorder.

Patients will receive 1 million or 2 million cells/kg IV CYP-001 given on days 0 and 7 in the open-label, U.K. and Australian trial. In addition to the primary safety endpoint, the trial will evaluate complete response (CR), partial response (PR) and overall survival (OS) rates at days 28 and 100...